Revised forecast
Fiscal year ending September 2026 · Full yearPrevious forecast published 11 November 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Sales of the AI/Voice Electronic Medical Record Integration System Revo.11, AI/Voice Periodontal Disease Precision Examination and AI/Voice Subchart, which form the core of the Company’s offerings, are expanding steadily, and higher revenue and profit are expected year on year and versus plan.
| Item | Details |
|---|---|
| Net Sales | ¥2,484 million → ¥2,503 million（+0.8%） |
| Operating profit | ¥562 million → ¥583 million（+3.7%） |
| Ordinary income | ¥662 million → ¥717 million（+8.3%） |
| Profit attributable to owners of the parent | ¥451 million → ¥481 million（+6.7%） |
| Net income per share | 202.7 yen → 215.9 yen |
| Fiscal Period Covered | Fiscal year ending September 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 11 November 2025 |
| Previous-period results | Revenue ¥2,406 million, operating profit ¥549 million, ordinary profit ¥652 million, net income ¥448 million, earnings per share ¥201.13 |
| Reason for the revision | Sales of the AI/Voice Electronic Medical Record Integration System Revo.11, AI/Voice Periodontal Disease Precision Examination and AI/Voice Subchart, which form the core of the Company’s offerings, are expanding steadily, and higher revenue and profit are expected year on year and versus plan. |
| Dividend forecast revision | The year-end dividend was changed from ¥44 to ¥50 (regular dividend ¥44, special dividend ¥6), and the annual dividend was increased from ¥88 to ¥94. |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales of the AI/Voice Electronic Medical Record Integration System Revo.11, AI/Voice Periodontal Disease Precision Examination and AI/Voice Subchart, which form the core of the Company’s offerings, are expanding steadily, and higher revenue and profit are expected year on year and versus plan. In addition to the expected increases in revenue and profit, a special dividend will be paid as a token of appreciation to shareholders as the Company reaches its 50th fiscal year.